- Home
- CERS vs THRD Comparison
CERS vs THRD Comparison
Compare CERS & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERS
- THRD
- Stock Information
- Founded
- CERS 1991
- THRD 2019
- Country
- CERS United States
- THRD United States
- Employees
- CERS N/A
- THRD N/A
- Industry
- CERS EDP Services
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- CERS Technology
- THRD Health Care
- Exchange
- CERS Nasdaq
- THRD Nasdaq
- Market Cap
- CERS 271.4M
- THRD 238.7M
- IPO Year
- CERS 1997
- THRD 2022
- Fundamental
- Price
- CERS $1.50
- THRD $5.43
- Analyst Decision
- CERS Strong Buy
- THRD Hold
- Analyst Count
- CERS 2
- THRD 3
- Target Price
- CERS $3.50
- THRD $5.00
- AVG Volume (30 Days)
- CERS 1.4M
- THRD 254.9K
- Earning Date
- CERS 07-31-2025
- THRD 08-07-2025
- Dividend Yield
- CERS N/A
- THRD N/A
- EPS Growth
- CERS N/A
- THRD N/A
- EPS
- CERS N/A
- THRD N/A
- Revenue
- CERS $185,144,000.00
- THRD N/A
- Revenue This Year
- CERS $24.95
- THRD N/A
- Revenue Next Year
- CERS $8.48
- THRD N/A
- P/E Ratio
- CERS N/A
- THRD N/A
- Revenue Growth
- CERS 13.06
- THRD N/A
- 52 Week Low
- CERS $1.12
- THRD $3.18
- 52 Week High
- CERS $2.54
- THRD $16.02
- Technical
- Relative Strength Index (RSI)
- CERS 54.05
- THRD 69.19
- Support Level
- CERS $1.31
- THRD $5.42
- Resistance Level
- CERS $1.46
- THRD $5.47
- Average True Range (ATR)
- CERS 0.07
- THRD 0.05
- MACD
- CERS 0.00
- THRD -0.01
- Stochastic Oscillator
- CERS 65.79
- THRD 75.00
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.